Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
Tanaka N, Izumi K, Nakai Y, Shima T, Kato Y, Mita K, Kamiyama M, Inoue S, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A. Tanaka N, et al. Among authors: enokida h. Prostate. 2024 Sep 20. doi: 10.1002/pros.24796. Online ahead of print. Prostate. 2024. PMID: 39301921
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M; Japanese Urological Oncology Group. Shiota M, et al. Among authors: enokida h. Ann Surg Oncol. 2024 Jun;31(6):3872-3879. doi: 10.1245/s10434-024-14999-2. Epub 2024 Feb 14. Ann Surg Oncol. 2024. PMID: 38353798
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
Miyake M, Kitamura H, Nishimura N, Miyamoto T, Nakahama T, Fujii T, Matsumoto H, Matsuyama H, Yonemori M, Enokida H, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Nishiyama H, Fujimoto K; Nishinihon Uro‐oncology Extensive Collaboration group and the Japanese Urological Oncology Group. Miyake M, et al. Among authors: enokida h. BJUI Compass. 2023 Nov 3;5(2):269-280. doi: 10.1002/bco2.305. eCollection 2024 Mar. BJUI Compass. 2023. PMID: 38371197 Free PMC article.
Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
Fukumoto W, Okamura S, Tamai M, Arima J, Kawahara I, Fukuda I, Mitsuke A, Sakaguchi T, Sugita S, Matsushita R, Tatarano S, Yamada Y, Nakagawa M, Enokida H, Yoshino H. Fukumoto W, et al. Among authors: enokida h. BMC Cancer. 2024 Oct 29;24(1):1333. doi: 10.1186/s12885-024-13109-5. BMC Cancer. 2024. PMID: 39472827 Free PMC article.
Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.
Kawahara I, Yoshino H, Fukumoto W, Arima J, Saito S, Li G, Fukuda I, Mitsuke A, Sakaguchi T, Inoguchi S, Matsushita R, Nakagawa M, Tatarano S, Yamada Y, Enokida H. Kawahara I, et al. Among authors: enokida h. Mol Oncol. 2024 Sep;18(9):2196-2211. doi: 10.1002/1878-0261.13684. Epub 2024 Jun 14. Mol Oncol. 2024. PMID: 38874588 Free PMC article.
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study.
Sakaguchi T, Mitsuke A, Osako Y, Yamada Y, Takeyama H, Ogawa R, Takahashi K, Hirohata Y, Yamamoto S, Arima J, Fukumoto W, Sugita S, Inoguchi S, Matsushita R, Yoshino H, Tatarano S, Enokida H. Sakaguchi T, et al. Among authors: enokida h. BMC Nephrol. 2024 Apr 8;25(1):124. doi: 10.1186/s12882-024-03561-7. BMC Nephrol. 2024. PMID: 38589827 Free PMC article.
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Mita K, et al. Among authors: enokida h. Cancers (Basel). 2024 Jan 24;16(3):508. doi: 10.3390/cancers16030508. Cancers (Basel). 2024. PMID: 38339260 Free PMC article.
183 results